

**Imagineering Technologies Inc.
Business Plan Executive Summary and
Introduction**

January 2025

**Dr. Henry Makowitz (Ph.D.)
CEO, Pres. and Exec VP for R&D**

**P.O. Box 2913
Idaho Falls, Idaho 83403-2913 USA**

**Tel: 208 524-2719
Cell: 208 881-4923**

Email

**hmakowitz@sisna.com
and
Imagineering99@yahoo.com**

Imagineering Technologies, Inc. intends to develop, and market Technology, Pharmaceuticals and Tools for Cancer Treatment. This includes Pharmaceuticals for the control of Radiation Susceptibility and Resistance, Heavy Ion Beam (Mostly Carbon Ions) Delivery Technology, Development of specialized Computers for DNA/RNA repair modeling, and Scanners for Very High Resolution and High Speed Cancer Detection.

The initial thrust of the R & D effort will be targeted at increasing the survival rate of Glioblastoma patients. 52 % of all primary brain tumors are categorized as Glioblastoma. Survival rates with surgery and chemo are very low. Two to three individuals per 100,000 per year are subjected to this illness. Most of them die within five years or less. There are 7.7 Billion persons living on planet earth. Glioblastoma results in approximately $2 - 3 \times 10^{**5}$ deaths per year. Imagineering Technologies Incorporated wants to establish a cost effective treatment for Glioblastoma with a target treatment cost of \$ 50 K USD per patient.

BUSINESS

The Company, Imagineering Technologies, Inc. intends to develop, and market Technology, Pharmaceuticals and Tools for Cancer Treatment. This includes Pharmaceuticals for the control of Radiation Susceptibility and Resistance, Heavy Ion Beam Delivery Technology, Development of Specialized Computers for DNA/RNA repair modeling, and Scanners for Very High Resolution and High Speed Cancer Detection. Development of new Antibiotics will also be investigated.

MARKET

The market for "**EFFECTIVE**" Pharmaceuticals for the control of Radiation Susceptibility and Resistance in Cancerous and Adjoining tissues maybe as large as \$10,000,000,000.00 (**\$ 10 Billion**) **per year**, based on Glioblastoma statistics, world wide. An **additional factor of 2x** maybe due to other localized Cancers. New more powerful Antibiotics may have a **Multi-Billion \$USD per year** market world wide. Although, genetic approaches to cancer treatment are projected to become the dominant technology of the future, **Imagineering** predicts that **at least 50% of all cancer treatment will still involve some radiation** procedures, and remain a market for its proposed Pharmaceuticals. Assuming a 20%

profit margin and capture of 50% of the market by Imagineering this would result in **\$ 1.0 Billion per Year in profit for the Company**, after a period of four to five years of R&D, and a number of years of clinical trials (i.e., two to three). This should be **compared to the proposed total stockholder investment, in three phases, of \$414.0 Million** over this time frame (i.e., \$1.00 Billion/ \$414.0 Million = **2.415 return on investment** in year eight). Similar returns can be obtained for new more powerful Antibiotics with minimal additional technological and financial risk to the Company. The market size for Heavy Ion Beam Delivery Technology, Specialized Computers for DNA/RNA repair modeling, and Scanners for Very High Resolution and High Speed Cancer Detection is based on the assumption that there are a hundred specialized customers in the world for these products. At \$ 5,000,000.00 (\$ 5.0 Million) a system, with three families of systems, (i.e., Accelerators, Computers, and Scanners) there is a \$1.50 Billion Dollar market. Assuming a 50% profit margin and capture of 50% of the market by Imagineering this would result in **\$375 Million in profit** for the company **over a period of six to seven years**, after four years of R&D.

The Company, Imagineering Technologies Incorporated, is conducting an equity stock offering as a REG D 506 (c).

The Company would like to raise \$ 4.00 M USD via this offering. These funds would allow the Company to operate for three to four years. This is the first of three equity stock offerings by the Company. The second offering is projected to be for \$ 10.0 M USD and will allow the Company to operate for another three to four years. The third offering will be an IPO and is projected to be for \$ 400.0 M USD. Please refer to the complete Business Plan and PPM for details of planned expenditures and R & D as well as product details.